【八大处整形医学概念验证中心.开放日】 开放日安排 14:00-14:30 一楼大厅集合，参观验证中心 14:30-15:00 会议室座谈 ：自我介绍 15:00-15:30 八大处整形医学概念验证中心及转化成果介绍 一、活动时间： 2025年 6 月27 日 星期五 14:00 二、活动地点 ： 北京·朗诚大厦 三、预计 规模： 20人左右 四、活动对象： （1）希望了解验证中心，探讨合作机会的各界朋友 （2）医美企业创始人、投资人、行业从业者 分享嘉宾：姚贵金 八大处整形集团副总经理、八大处整形医学概念验证中心负责人 八大处整形医学概念验证中心是国内首家专注整形外科科技成果转化的专业平台，依托中国医学科学院整形外 科医院，聚焦材料、器械、药械结合类创新，为医生、企业、研发团队提供"从概念到产品"的支持与协作网 络。 15:30-16:00 自由交流 报名方式 复制以下链接到IE浏览器进行填写或点击文末 "阅读原文" 进行填写 https://docs.qq.com/form/page/DZmdBbFhUR1ZEaEJ5 或扫描下方二维码进行填写 ...

环球市场动态 内 地 财 政 对 资 金 面 压 力 将 明 显 增 加 股 票 以色列伊朗停战，全球股市情绪大 幅反弹。A 股上涨，沪指重回 3400 店；港股全线上涨，权重的科技股、 金融股纷纷走高；欧洲交易时段尽 管以色列和伊朗双方都指责对方破 坏停火协议，但市场乐观情绪仍较 高推动强劲收涨；鲍威尔国会证词 提及降息，美股三大指数均涨超 1%，金龙中国指数涨 3%。 外 汇 / 商 品 以伊停火协议缓解供应担忧，并且 特朗普表示中国可以继续购买伊朗 石油，原油价格连续第二天重挫； 中东局势降温减弱避险需求，周二 国际金价下跌近 2%；美国消费者 信心弱于预期，鲍威尔降息前景发 出偏平衡的信号，美元指数下跌 0.6%至 97.86。 固 定 收 益 美国短期国债领涨；地缘政治局势 缓和；美国消费者信心意外下降； 鲍威尔重申观望立场，未排除 7 月 降息可能；两年期美债拍卖中标利 率略低于发行前水平，需求略显平 淡。亚洲债市情绪改善，中国投资 级债券利差收窄 1-3bp。 产品及投资方案部 注：bp/bps=基点；pt/pts=百分点 中信证券财富管理 (香港) 免责声明请参考封底 2025 年 6 月 2 ...

Group 1 - The recent tensions in the Middle East have led to a temporary impact on A-share market sentiment, but the market has rebounded, with the Shanghai Composite Index reaching a new high in nearly a month [1] - The market is expected to maintain a slow upward trend as it approaches the policy window period at the end of June, with potential for new policies aimed at stabilizing employment and promoting high-quality development [1] - Popular sectors such as banking and innovative pharmaceuticals may experience short-term fluctuations due to accumulated gains, while TMT and technology growth sectors are anticipated to see a rebound after sufficient adjustments [1] Group 2 - The outlook for July suggests a theme-driven market with high-low sector rotation, as popular sectors like innovative pharmaceuticals and banking have shown signs of correction, while TMT and advanced manufacturing sectors are beginning to rebound [2] - Key focus areas for 2025 include expanding domestic demand and consumption, with expectations for policies to support sectors like dairy products, IP consumption, leisure tourism, and medical aesthetics [2] - The trend towards domestic production of robotics is expected to continue, with opportunities arising in sensors, controllers, and functional robots [2] - The semiconductor industry is projected to see continued domestic growth, with attention on semiconductor equipment, wafer manufacturing, materials, and IC design [2] - The military industry is anticipated to experience a rebound in orders by 2025, with signs of recovery already visible in various sub-sectors [2] - The innovative pharmaceutical sector is expected to reach a turning point in fundamentals by 2025, following a period of adjustment [2] - The AI sector is poised for new catalysts, with significant updates expected from companies like MiniMax, indicating a resurgence in AI-related investments [2] Group 3 - The A-share market has ended a month-long period of consolidation, with the Shanghai Composite Index reaching a new high, supported by a broad-based rally among individual stocks [3] - The market saw a significant increase in the number of rising stocks, with over 4,700 stocks gaining, while only a few sectors like oil and coal experienced declines due to falling international oil prices [3] - Leading sectors included electric power equipment, non-bank financials, retail, automotive, and machinery [3]

关注资本市场的趋势与发展 以下文章来源于信风TradeWind ，作者郑敏芳 信风TradeWind . 作者 | 郑敏芳 起因正是新氧自营诊所复配的童颜针"艾维岚"产品（又称"奇迹童颜"）售价仅为5999元， 为市场公价的1/3，这引发了艾维岚品牌方长春圣博玛生物材料有限公司（下称"圣博 玛"）的不满。 笔者注意到，新氧早在2023年就与上游医美材料商东方妍美（成都）生物技术股份有限公 司（下称"东方妍美"）达成战略合作，后者将尚未上市的童颜针XH301等多款产品的国内 商业化权利独家授权给新氧。 随着此番东方妍美踏上港股IPO之路，其XH301的上市进展情况得以披露。 作为东方妍美的核心产品，XH301预计今年下半年完成国内上市审评，欧盟上市注册进程 则处于提交阶段。 来源 | 信风TradeWind 圣博玛发文指出，不对新氧诊所销售的艾维岚提供正品保证责任；新氧则强调旗下产品均 为正品，指责圣博玛的说法是"无端抹黑"。 导 语： 圣博玛发文指出，不对新氧诊所销售的艾维岚提供正品保证责任；新氧则强调旗下 产品均为正品，指责圣博玛的说法是"无端抹黑"。 童颜针价格战一触即发。 6月19日，新氧CEO金星发文 ...

Core Viewpoint - New Oxygen Technology (NASDAQ: SY) is facing a dual challenge of declining revenue and increasing losses, with significant fluctuations in performance over recent years [1][2] Financial Performance - In 2024, New Oxygen's total revenue is projected to be 1.467 billion yuan, a year-on-year decrease of 2.09% - Gross profit is expected to be 899 million yuan, down 5.72% year-on-year - Net loss is anticipated to reach 587 million yuan, with a net loss attributable to New Oxygen International of 590 million yuan [1] Recent Quarterly Results - In Q1 2025, New Oxygen's total revenue was 297 million yuan, a year-on-year decline of 6.6% - Net loss expanded to 33.1 million yuan, a 56.13% increase compared to the 21.2 million yuan loss in the same period of 2024 - Gross margin decreased from 63% in Q1 2024 to 49% in Q1 2025, indicating a significant decline in profitability [1] Business Challenges - The primary reason for New Oxygen's negative revenue growth is the severe impact on its traditional core business, "Information and Appointment Services" - This segment, which accounted for 100% of revenue in 2020, saw revenue drop from 1.151 billion yuan in 2023 to 929 million yuan in 2024, reducing its share to 63.4% - Emerging platforms like Douyin and Xiaohongshu are diverting advertising budgets from medical beauty institutions, while comprehensive platforms like Alibaba Health and Meituan are capturing market share due to their traffic advantages, leading to a significant reduction in the number of subscribed institutions [2]

Core Insights - The 2025 New Fortune 500 Rich List highlights AI as a major driving force for wealth creation among the top entrepreneurs [1][3] - The geographical focus of China's economy is shifting, with a notable increase in wealth concentration in Zhejiang, particularly Hangzhou, while Guangdong's representation has decreased significantly [2][10] Group 1: Wealth Distribution and Rankings - The total market value of the 500 entrepreneurs on the list is 13.7 trillion yuan, an 11% increase year-on-year, with an average market value of 27.38 billion yuan per individual [3] - Zhang Yiming, founder of ByteDance, tops the list with a valuation of 481.57 billion yuan, marking a significant rise from 12 billion yuan seven years ago [4] - ByteDance's revenue reached 155 billion USD in 2024, a 29% increase, with a net profit of 33 billion USD, making it the leading internet technology company in China [5] Group 2: Industry Trends and Emerging Entrepreneurs - The TMT (Technology, Media, and Telecommunications) sector leads the list with 110 entrepreneurs, a significant increase of 22 from the previous year, contributing 3.34 trillion yuan, or 25% of the total wealth on the list [7] - The semiconductor industry is identified as a key wealth generator within the TMT sector, with notable figures like Chen Tian Shi of Cambrian holding a market value of 78.6 billion yuan, a 370% increase [7] - New entrants in emerging fields such as humanoid robotics and industrial robotics are also highlighted, with notable figures like Wang Xingxing of Yushutech making their debut on the list [8] Group 3: Regional Wealth Dynamics - Guangdong remains the province with the highest number of listed entrepreneurs, though its count has dropped from 112 in 2021 to 96 in 2025, with total wealth decreasing from 4.5 trillion yuan to 3 trillion yuan [10] - Zhejiang has seen a rise in representation, with 76 entrepreneurs, surpassing Beijing, which has seen a decline from 83 to 70 [13] - The rise of the Yangtze River Delta region is evident, with Shanghai and Jiangsu also increasing their number of listed entrepreneurs, driven by sectors like semiconductors and consumer spending [13][14]

Group 1 - The stock price of New Oxygen surged by 41.88% on Monday, reaching $1.66 per share and a market capitalization of $166 million, following a previous increase of 15.84% [1] - New Oxygen's stock had been underperforming since its NASDAQ debut in May 2019, where it initially rose by 31.88% to a market cap of approximately $1.823 billion [1] - Analysts attribute the recent stock surge to strong growth in the company's chain business, while advertising and upstream businesses remain undervalued [1] Group 2 - Founded in 2013, New Oxygen initially focused on an internet medical beauty platform, achieving rapid revenue growth from 49 million RMB in 2016 to 617 million RMB in 2018, with a compound annual growth rate of 254.85% [2] - The company has faced significant challenges in recent years due to competition from platforms like Alibaba Health and Meituan, as well as content e-commerce platforms like Douyin and Xiaohongshu [2] - New Oxygen plans to launch a new light medical beauty chain brand "New Oxygen Youth Clinic" in November 2024, aiming to reduce costs through centralized procurement and improve service efficiency [2] Group 3 - As of March 31, 2025, New Oxygen operates 23 medical beauty centers across nine major cities in China, with 18 centers achieving positive monthly cash flow [2] - The company reported a significant increase in quarterly write-off projects, exceeding 92,900, and a growth in quarterly paid users by 874% to over 45,500 [2] - Active user numbers surpassed 75,700, reflecting an 846% year-on-year increase, indicating enhanced user engagement [2] Group 4 - New Oxygen has recently been involved in disputes regarding its "Miracle Youth" project, which offers a product at a significantly lower price than the official price set by the manufacturer [3] - The company defends its product authenticity and compliance, while accusing competitors of unfair practices [3]

Core Insights - The medical beauty industry, particularly the hyaluronic acid market, is experiencing rapid growth, with major players like Aimeike, Huaxi Biological, and Haohai Biological achieving significant revenue increases and maintaining high gross profit margins, although there are signs of potential declines in these margins due to increased competition and market saturation [1][2][7][8] Group 1: Sales and Profitability - The overall gross profit margin for the leading companies in the hyaluronic acid market remains above 70%, with Aimeike reaching a peak margin of 95% by 2024, while Huaxi Biological and Haohai Biological are projected to see declines in their margins to 74.07% and 69.52% respectively by 2024 [1] - Aimeike's injection products contribute nearly 98% of its total revenue in 2024, with sales of solution-type injections reaching 1.744 billion and gel-type injections at 1.216 billion [8] Group 2: Business Development Strategies - Haohai Biological has pursued a strategy of mergers and acquisitions since 2007, completing nearly 20 transactions to expand its business into various sectors, including ophthalmology and medical aesthetics, with medical beauty and wound care projected to generate 1.195 billion in revenue in 2024, reflecting a 13.06% year-on-year growth [2][5] - Huaxi Biological has diversified its business model since 2012, moving from raw material supply to include medical, functional skincare, and functional food sectors, with functional skincare sales expected to reach 2.569 billion in 2024, accounting for 47.84% of total revenue [7]

Group 1 - The core issue revolves around the dispute between two major players in the medical beauty industry, Juzi Biotechnology and Huaxi Biotechnology, regarding recombinant collagen products [2] - Juzi Biotechnology acknowledged limitations in its current quality standards, testing methods, and labeling, which are not fully aligned with the industry's evolving high standards and technological advancements [2][7] - Following the announcement, Juzi Biotechnology's stock price surged over 7% on June 24 [3] Group 2 - Juzi Biotechnology outlined three future initiatives: collaborating with research institutions to enhance testing methods for recombinant collagen in cosmetics, gradually disclosing key technical parameters and quality control data, and actively participating in the formulation of national and industry standards for recombinant collagen [7] - Huaxi Biotechnology previously addressed concerns about the lack of relevant testing standards in the recombinant collagen sector, emphasizing the misuse of the term "collagen" and the need for clear scientific conclusions to avoid misleading the market and consumers [10]

6 月 23 日晚，巨子生物在官方微信公众号发布关于重组胶原蛋白产品有关问题的说明，明晰 了自查结果和下一步措施。 巨子生物承认： " 我公司现有的质量标准、检测方法和标签标识在某些方面已逐渐显现出其 局限性，难以完全适配行业发展与技术进步的高标准和高要求。 " 【导读】巨子生物回应重组胶原蛋白产品问题 中国基金报记者 赵心怡 两大医美巨头 —— 巨子生物和华熙生物之间的纷争迎来 " 最终章 " 。（此前详情可参考报 道《 价值研究所｜撕扯、炒作？美妆巨头成分 " 罗生门 " 》） 6 月 24 日开盘，巨子生物股价一度大涨超 7% 。 巨子生物：检测标准和方法存在局限性 从现有行业标准来看，发布和实施日期基本集中在近 5 年，目前最新的一版是 2025 年发布 的医药行业标准 YY/T 1947-2025 《重组胶原蛋白敷料》，将于 2026 年 3 月实施。 巨子生物表示： " 随着重组胶原蛋白产业的快速发展，以及消费者对产品质量要求的日益增 长，我公司现有的质量标准、检测方法和标签标识在某些方面已逐渐显现出其局限性，难以 完全适配行业发展与技术进步的高标准和高要求，需要不断优化迭代。 " 对于未来发展， ...